MAM
GLUE icon

Meeder Asset Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Meeder Asset Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,050
Closed -$53.3K – 944
2024
Q3 		$53.3K Hold
10,050
– – ﹤0.01% 355
2024
Q2 		$37.6K Buy
+10,050
New +$51.2K ﹤0.01% 394

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Meeder Asset Management's GLUE Position: Q4 2024 in Review

Meeder Asset Management sold out of Monte Rosa Therapeutics (GLUE) in Q4 2024, closing a stake of 10,050 shares — an estimated $53.3K sold.

Meeder Asset Management first reported a position in GLUE in Q2 2024 and held it in 2 quarters. The position peaked at $53.3K in Q3 2024. 104 funds tracked by Wall St. Rank hold GLUE as of Q4 2024.

  • Meeder Asset Management reported no remaining Monte Rosa Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Meeder Asset Management sold 10,050 Monte Rosa Therapeutics shares in Q4 2024, an estimated $53.3K.
  • Meeder Asset Management first reported a position in Monte Rosa Therapeutics in Q2 2024 and held it in 2 quarters.
  • Meeder Asset Management's Monte Rosa Therapeutics position peaked at $53.3K in Q3 2024.
  • 104 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q4 2024.

Based on Meeder Asset Management's 13F filing for Q4 2024, filed 12 Feb 2025.